US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.810 -0.410 (-5.68%)
Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
War On Drugs 'Has Failed, Completely And Utterly': UN High Commissioner Urges Evidence-Based Solutions ↗
UN calls for evidence-based, human rights-focused approach to drug policies, declaring the failed war on drugs needs to be abandoned. Urges transformative change and adoption of International... 
Via Benzinga
News headline image
Why Emergent BioSciences Stock Plummeted Today ↗
Via The Motley Fool
News headline image
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement ↗
 
Via Benzinga
News headline image
From GLD To TSLA: Unlocking Today’s Best Trading Opportunities ↗
The week kicks off amidst significant market movements shaped by geopolitical and policy developments. 
Via Talk Markets
Topics Stocks / Equities
News headline image
After Trump's Win, It's Time To Take Profits On Gold ↗
 
Via Benzinga
Topics Government
News headline image
Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise ↗
The U.S. overdose crisis and its racial disparities were overlooked in the election, as Black and Indigenous Americans face rising death rates. 
Via Benzinga
Topics Death
News headline image
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 ↗
Emergent BioSolutions stock rises on mixed Q3 results, improved 2024 guidance, and news of a new trial for mpox treatment in Africa led by the CDC. 
Via Benzinga
News headline image
Crude Oil Rises 1%; US Jobless Claims Increase To 221,000 ↗
 
Via Benzinga
News headline image
Gold Gains 1%; Halliburton Posts Weak Q3 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
The Post-Trump Victory Trade ↗
The Trump Trade. 
Via Benzinga
Topics Government
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript ↗
EBS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
From Emergent BioSolutions
Via GlobeNewswire
News headline image
What's Going On With Emergent BioSolutions Stock Wednesday? ↗
Emergent BioSolutions stock is trading higher after the company announced the closing of a $100 million asset-backed revolving loan facility. 
Via Benzinga
News headline image
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
From Emergent BioSolutions
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines ↗
Emergent BioSolutions secures $400M in orders for smallpox and mpox products, receives FDA approval for ACAM2000's expanded use, and updates its 2024 revenue forecast while beating Q2 sales estimates. 
Via Benzinga
News headline image
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >